behzad asanjarani

The COVID-19 pandemic is a traumatic event with a global impact, predicted to increase depression, anxiety, substance use, sadness, and loneliness. This study was conducted to evaluate the scale of depression, anxiety, and stress among patients infected with the COVID-19 virus.

This cross-sectional study was conducted between April 2019 and April 2022. According to the conditions of the study space, available sampling was selected. In addition to demographic characteristics, a questionnaire related to stress, anxiety, and depression (DASS-21) was used to collect data. Then, the collected data were entered into SPSS software for analysis, and Pearson's correlation was used to check the relationship between the variables, with the significance level (P-value) reported.|

Out of a total of 714 participants, 26.1% had higher scores in depression, 37.5% in anxiety, and 15.7% in stress. In this way, two-thirds of the studied population on the depression and anxiety scale and almost half of the studied population on the stress scale experienced degrees of these disorders from mild to very severe during the period of COVID-19 infection. The scores of each subcategory of depression, anxiety, and stress are significantly correlated with each other, which shows that people who have a higher score in one subcategory also have a higher score in two subcategories.

It seems that COVID-19 has an obvious effect on the mental health of people. Thus, more policies and attention are needed in this field to manage the disease.

GTN (Gestational trophoblastic neoplasm) complications such as uterine rupture or massive bleeding can be life-threatening and usually need a hysterectomy. In young patients who want to preserve fertility, hysterectomy is not suitable. Under specific circumstances, some physicians choose conservative management. Uterine preservation after complicated GTN is rare by itself. In conclusion, conservative management of GTN patients who develop high-risk complications and desire for future pregnancies must be considered an option. In published case reports, outcomes of conservative surgical management have been very good if managed properly.

Routine blood testing consists of Complete Blood Count (CBC) indices together with Comprehensive Metabolic Panel (CMP) which have significant roles in both diagnosis and prognosis of the novel coronavirus disease 2019 (COVID-19).  A total number of 942 COVID-19 patients and 400 healthy persons as the control group were enrolled in this study. All patients were admitted to a single center and were divided into two groups according to disease severity (severe or non-severe). Routine laboratory findings of peripheral blood sample were collected and then analyzed.  Neutrophil-Lymphocyte Ratio (NLR) had the highest sensitivity and specificity value for COVID-19 diagnosis. Among patients with different severities of COVID-19, the amount of neutrophil, NLR, platelet, hemoglobin, Red cell Distribution Width (RDW) and total bilirubin was significantly different (p<0.01).  Some indices of complete blood count and comprehensive metabolic panel have diagnostic and prognostic roles in COVID-19 patients, which are helpful in early diagnosis, predicting severity and adverse outcomes of patients with COVID-19.

The outbreak of new pathogens or the resurgence of pathogens that have already spread is a serious challenge to public health. Coronavirus is a pathogen that seems to invade the human respiratory system in the first place. Coronaviruses form a large family and are so called because of the presence of crown like cristae on their surface.

This is a cross‑sectional, descriptive study conducted to assess the status of patients with COVID‑19 who were hospitalized in an educational hospital. For this purpose, 142 patients hospitalized in this hospital were followed up 2 weeks after discharge and were inquired about the symptoms they had upon admission to the hospital, the number of hospitalization days, the history of underlying disease, and so on. Descriptive data analysis was done with the SPSS software version 22.

The findings of this research showed that overweight or obese people (about 66%) is more likely to contract the disease. It also seems that older people (37.3% older than 60 years old) and those with a history of diseases (69.6%) such as diabetes, high blood pressure, or heart disease are more prone to COVID‑19. The most common symptoms of COVID‑19 patients included fever (64.5%), shortness of breath (67.4%), and dry cough (50.4%).

it seems that high risk group (obese people, old people, and people with a history of disease) is more likely to be infect with coronavirus so they should more careful than others. Another important issue is that policy‑makers must play an active role in public awareness of dangers of COVID‑19 and ways to prevent it.

Lactose intolerance is common in Asian population. Enzyme replacement therapy facilitates consumption of milk and dairy products for patients with lactose intolerance. Clinical evidence in our clinics indicates a nonhomogeneity in improvement of symptoms after ingestion of solid form of exogenous lactase enzyme in patients. Therefore, we designed this study to evaluate the effectiveness of oral solid lactase enzyme in the clinical symptoms of patients with lactose intolerance in Arak city. This randomized double blind placebo controlled trial was performed on 50 adult symptomatic patients with lactose intolerance. Average age of the patients was 37.4 years and 44% were men. Every patient took lactase and placebo for one week respectively. Effects of these treatments on gastrointestinal symptom of patients were gathered by symptom evaluation questionnaire. Results were analyzed by SPSS software. The mean improvement of abdominal pain score after lactase was 1.56 ± 2.51 (P < 0.001) and after placebo was 0.54 ± 0 (P < 0.001). The mean improvement of flatulence score after lactase was 1.6 ± 1.91 (P < 0.001) and after placebo was 0.42 ± 0.94 (P = 0.03). The mean improvement of bloating score after lactase was 1.62 ± 1.79 (P < 0.001) and after placebo was 0.56 (P < 0.001) ± 0.88. The mean improvement of diarrhea score after lactase was 2.70 ± 3.06 (P < 0.001) and after placebo was 0.54 ± 0.99 (P < 0.001). The mean improvement of nausea and vomiting score after lactase was 0.24 ± 0.89 (P = 0.63) and after placebo was 0.04 ± 0.19 (P = 0.15). After ingestion of lactase, 19 patients had no improvement in abdominal pain score, 12 patients in flatulence score, 3 patients in nausea and vomiting score, 17 patients in bloating score, and 7 patients had no improvement in diarrhea score. Lactase tablets significantly reduced clinical symptoms associated with lactose intolerance compared with placebo; but improvement of symptoms were variable between patients.